Navigation Links
VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Date:1/7/2008

in the third quarter of 2008 from this study.

The CEA study is designed to evaluate the efficacy of VIA-2291 in the vessel wall, and has the unique advantage of providing access to atherosclerotic tissue for direct evaluation of VIA-2291's effect on inflammation, through a panel of assays and histological examinations.

Acute Coronary Syndrome (ACS) Study

The ACS study has enrolled more than two-thirds of the targeted 200 patients for this trial and top-line data results are anticipated to be released shortly after the release of data from the CEA trial. This study is designed to establish dose and safety data in patients with acute coronary syndrome (ACS) who have experienced a recent heart attack, and includes measures of leukotrienes, biomarkers of inflammation as well as medical imaging of the coronary vessel wall to evaluate impact on plaque characteristics.

About VIA-2291

VIA-2291 is a selective and reversible inhibitor of 5-LO, which is a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). Potentially a complement to current standard of care therapies that treat risk factors, such as statins, antiplatelet and blood pressure medications, VIA-2291 is initially targeted to address the secondary prevention market for patients who have already suffered a major adverse cardiovascular event, but eventually could be beneficial to the broader 15.8 million patients in the U.S. who have coronary artery disease. VIA has exclusive worldwide rights to develop and commercialize VIA-2291. Based upon prior trials of VIA-2291 in more than 1,100 patients, VIA believes that VIA-2291 will be safe and well tolerated in doses currently being administered in the ongoing clinical trials.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovas
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Tianyin Pharmaceutical Co., Inc. ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today updates the timeline for the ... The Company is scheduled to ... China Food & Drug Administration,s (CFDA) review in ...
(Date:8/28/2014)... 28, 2014  Decision Resources Group finds that the market ... $7.7 billion by 2023 in the United States ... , Italy , Spain ... Japan . The biosimilar erosion of Roche/Genentech/Chugai,s ... out by the launch of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s ...
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
Breaking Medicine Technology:TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2
... BEIJING, March 1, 2011 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical ... or the "Company"), an emerging leader in the ... and homecare medical products in China, today announced ... community conferences in March: (Logo: ...
... Diagnostics, Inc. announced today that the WARFARIN Study ( W ... or A dults R eceiving Genetic Testing at ... nationwide to assess the utility of genetic testing to determine ... risk of serious bleeding or clotting events. Warfarin, the most ...
Cached Medicine Technology:Dehaier Medical Announces March Investor Presentations 2WARFARIN Study Launched to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 2WARFARIN Study Launched to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin 3
(Date:8/28/2014)... 28, 2014 Gurnick Academy of Medical ... program is re-accredited for the 5 years of the ... Technologists (ARMRIT). , “We are very proud to ... our program to make sure we provide the best ... interest in MRI field nowadays and I look forward ...
(Date:8/28/2014)... A chronic problem in winemaking is "stuck fermentation," when ... alcohol and carbon dioxide prematurely shuts down, leaving the ... can spoil the wine. , A team of researchers ... a biochemical communication system behind this problem. Working ... can reproduce itself -- the system enables bacteria in ...
(Date:8/28/2014)... of Medicine published research results on Aug. 21 ... safely reduce the viral load and clinical illness of ... (RSV). , Le Bonheur Children,s Hospital and ... Disease Specialist John DeVincenzo, MD, is lead author of ... common cause of lower respiratory tract infections in young ...
(Date:8/28/2014)... smoking kills approximately 440,000 Americans each year, according ... It,s the leading cause of preventable death worldwide. ... resort to nicotine replacement therapies. , A ... University of Miami (UM) suggest that small dosages ... harmful to human musculoskeletal system, due to overuse. ...
(Date:8/28/2014)... Lifesmart (formerly Source Network Sales and ... saunas, spas and hot tubs, today unveiled its entry ... purifiers, and price point multi-function tower fans. , “These ... established product lines and they will help us even ... less dependent on fourth quarter weather trends. Additionally ...
Breaking Medicine News(10 mins):Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2Health News:Prions can trigger 'stuck' wine fermentations, researchers find 2Health News:DeVincenzo study breakthrough in RSV research 2Health News:Are cigarette substitutes a safe alternative? It depends on user habits 2Health News:Are cigarette substitutes a safe alternative? It depends on user habits 3Health News:Lifesmart Unveils New Line of Air Conditioners, Dehumidifiers, Humidifiers, Air Purifiers and Price Point Multi-Function Tower Fans Expanding the lifesmart zone Brand 2
... By Amanda Gardner HealthDay Reporter , TUESDAY, April ... take calcium supplements to prevent bone deterioration may, in fact, be ... previous studies with similar findings, the new conclusions don,t necessarily mark ... study released online April 19 in the BMJ . ...
... at the University of Pennsylvania School of Medicine are delving ... of chromosomes. Recent work, e-published in Nature Structural & ... telomeres, can be protected by caps made up of specialized ... Telomere caps are like a knot at the end of ...
... major discovery about an enzyme,s structure has opened a window ... have determined the structure of a nuclease that will help ... for cancer research. DNA repair pathways are very important ... tools the cell uses to do those repairs are not ...
... that will test whether heart disease drugs can be used ... class of drugs - known as statins - can prevent ... cent of pregnant women in the UK. The ... research showing that statins, which are prescribed to lower heart ...
... HealthDay Reporter , TUESDAY, April 19 (HealthDay News) -- ... to curb misuse of extended-release and long-acting opioid pain killers ... Risk Evaluation and Mitigation Strategy (REMS) is part of a ... reduce overall prescription drug abuse in the United States. ...
... The European College of Neuropsychopharmacology (ECNP) is pleased ... the 2011 ECNP Neuropsychopharmacology Award in Basic Science ... the brain adenosine system. The ECNP Neuropsychopharmacology Award ... neuropsychopharmacology and closely related disciplines. The award is ...
Cached Medicine News:Health News:Women Taking Calcium Supplements May Risk Heart Health, Researchers Say 2Health News:Women Taking Calcium Supplements May Risk Heart Health, Researchers Say 3Health News:Ends of chromosomes protected by stacked, coiled DNA caps 2Health News:Ends of chromosomes protected by stacked, coiled DNA caps 3Health News:Nature's elegant solution to repairing DNA in cancer, other conditions 2Health News:Heart drugs could cut blood pressure risks in pregnancy 2Health News:FDA Looks to Crack Down on Misuse of Opioid Painkillers 2Health News:Bertil Fredholm wins the 2011 ECNP Neuropsychopharmacology Award in basic science research 2
Stainless steel. Lamp is in fiberoptic handle. Green color coding. The blade includes a port that permits delivery of oxygen or other gas mixtures during intubation....
... of the vocal cords in even the most ... like a standard laryngoscope, Viewmax® does not require ... its ability to allow intubation whether you are ... airway. It has a patented lens system that ...
... Stainless steel. Lamp supplied with ... operate on any standard/conventional handle allowing ... illumination without the potential confusion from ... blades offer an easy and cost ...
... The FR-120F, Fujinon's new fiberoptic Naso-Pharyngo-Laryngoscope provides ... patient comfort. The latest in Fujinon ... increased light guide, and a wide 90 ... impressive 3.3mm distal tip diameter. In ...
Medicine Products: